{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-083290","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2022-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.124544+00:00","generated_at":"2026-06-20T22:26:38.562477+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Relmada extends key man provisions in esmethadone license to Dec 31, 2027","bullets":["Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.","Licensor may terminate license if CEO Sergio Traversa is fired without cause or his role is materially reduced.","License covers esmethadone (REL-1017) for psychiatric use; no other terms of the license were changed.","Extension locks in CEO-linked protections for an additional five years through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-083290","json":"https://secwatch.observer/filing/0001213900-22-083290.json","markdown":"https://secwatch.observer/filing/0001213900-22-083290.md","text":"https://secwatch.observer/filing/0001213900-22-083290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/0001213900-22-083290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/ea170963-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T22:26:38.562477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcf611c82076497421a6b64783aab0c9369eea1b","claim":"RELMADA THERAPEUTICS, INC. amended License Agreement with Drs. Charles E. Inturrisi and Paolo Manfredi (effective 2022-12-27).","evidence_excerpt":"On December 27, 2022, the Licensor and the Company entered into an Amendment No. 2 to the License Agreement extending the duration of the “Key Man” provisions of the License Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/0001213900-22-083290-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Drs. Charles E. Inturrisi and Paolo Manfredi"},{"label":"Effective","value":"2022-12-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}